TVTXTravere Therapeutics, Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M+12.8% YoY

Gross Profit

$53M97.0% margin

Operating Income

-$35M-64.7% margin

Net Income

-$39M-71.4% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+15.2%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$2M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$747M

Total Liabilities

$414M

Stockholders' Equity

$332M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$48M	+12.8%
Gross Profit	$53M	$47M	+12.8%
Operating Income	-$35M	-$23M	-52.8%
Net Income	-$39M	-$26M	-49.7%

Revenue Segments

Tiopronin Products

$30M54%

Bile Acid Products

$25M46%

TVTX Q2 2021 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena